Sharemaestro Newsreel

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Is iRhythm Holdings (IRTC) Undervalued Following Earnings And Higher 2026 Guidance?

Stronger Results, Bigger Buyback and More Credit Capacity Might Change The Case For Investing In Cardinal Health (CAH)

What Pfizer (PFE)'s EMA Lyme Vaccine Filing and Updated Outlook Means For Shareholders

Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake

Squadron Master Fund LP and related entities, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have reported a beneficial ownership stake of 810,000 shares in Lipocine Inc. (LPCN). This represents 9.8% of the company's outstanding shares as of May 6, 2026. The …

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics

The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection) for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology. Lantheus plans to support Alzheimer's therapeutic programs and is evaluating commercial …

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies …

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with …

Beyond Air Inc (XAIR) Stock News Today

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

PTCT Maintained by Barclays -- Price Target Raised to $122

Barclays has maintained an "Overweight" rating for PTC Therapeutics (PTCT) and increased its price target to $122.00 from $120.00. Despite this positive analyst outlook, GuruFocus indicates the stock is significantly overvalued at $71.52 against a GF Value of $37.55, with a mixed GF Score …

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported a beneficial ownership of 9.96% in CytomX Therapeutics (CTMX). This group collectively holds shared voting and dispositive power over 21,703,093 shares of common stock. The disclosure was made …

Innovative Eyewear Q2 EPS $(0.26) beats estimate, sales rise 74%

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a …

Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares

Highbridge Capital Management, LLC has disclosed a beneficial ownership of 6.1% in Annovis Bio, Inc., which is tied to 2,775,578 shares of common stock issuable upon the exercise of warrants. This stake is calculated based on 42,541,868 outstanding common shares after a referenced offering …

Llamada de resultados del T2 de 2026 de Dyadic International (DYAI): progreso comercial y riesgo de liquidez

Dyadic International (DYAI) reportó ingresos estables en el segundo trimestre de 2026 de $961,000, con una pérdida neta que aumentó a $2.1 millones, y sus ingresos del primer semestre crecieron un 52% a $2.1 millones. A pesar de los progresos comerciales, la empresa finalizó …

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movement, making CDXS an attractive investment. The …

Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is …

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Quanterix Insider Bought Shares Worth $286,354, According to a Recent SEC Filing

An insider at Quanterix Corporation (QTRX) recently purchased shares valued at $286,354, according to a new SEC filing. This transaction was published on August 14, 2026, at 04:11 pm EDT. The article also provides recent news on Quanterix, including their Q2 2026 earnings results …

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for Upstream Bio (NASDAQ:UPB) to $9.00 from $8.00, maintaining a "neutral" rating. This new target suggests a potential upside of 29.22% from the stock's current price of $6.96. The company recently reported a quarterly loss …

Sensus Healthcare, Inc. Q2 2026: Revenue $2.29M, EPS $(0.53) — 10-Q Summary

Sensus Healthcare, Inc. (SRTS) reported a significant decline in its Q2 2026 financial results, with revenue falling to $2.29M and diluted EPS at $(0.53). This downturn was primarily attributed to fewer system sales, a shift towards Fair Deal Agreements and rental arrangements impacting revenue …

Butterfly Network (NYSE:BFLY) Shares Down 4.4% - Here's What Happened

Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Here's Why

Twist Bioscience (NASDAQ:TWST) Trading Down 4.3% - Here's What Happened

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …

HTFL Maintained by Wells Fargo -- Price Target Raised to $39

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy